CASE REPORTS
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Reversal of fortune: induced endoleak to resolve neurological deficit after endovascular repair of thoracoabdominal aortic aneurysm.

PURPOSE: To describe a direct anatomical treatment approach using an induced type Ib endoleak to increase spinal cord perfusion and reverse paraplegia occurring after endovascular exclusion of a type 2 thoracoabdominal aortic aneurysm (TAAA).

TECHNIQUE: The approach is illustrated in an 82-year-old woman who underwent branched endovascular repair of an asymptomatic, 6.8-cm-diameter type 2 TAAA. In 4-hour procedure, 3 aortic components were implanted beginning 50 mm distal to the origin of the left subclavian artery and ending 33 mm proximal to the aortic bifurcation. Upon awakening, the patient had sluggish movement in her legs. She responded to vasoactive agents and cerebrospinal fluid (CSF) drainage, but 3 recurrent episodes of paraplegia within 24 hours and severe headache indicated that the limits of CSF drainage had been reached. The patient was taken back to the operating room, and a type Ib (distal) endoleak was created by placing a balloon-expandable stent between the distal end of the infrarenal stent-graft component and the aortic wall, partially re-establishing flow into the aneurysm. The patient had no further recurrence of lower extremity paraplegia or paraparesis. At 3.5 months postoperatively, a Palmaz stent was deployed inside the distal end of the infrarenal stent-graft component to crush and occlude the Express LD stent, re-establishing a complete seal to preclude flow into the aneurysm. The patient remains clinically stable without lower extremity neurological deficit 3 months after the last procedure and 7 months after endovascular TAAA repair.

CONCLUSION: A direct anatomical approach to reverse spinal cord ischemia following endovascular TAA or TAAA repair is feasible by creating a type I or type III endoleak to afford partial, temporary reperfusion of the excluded aorta.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app